科伦药业(002422.SZ)子公司在2025年欧洲肿瘤内科学会大会上公布多项创新药物研究成果

Core Insights - The company announced that its subsidiary, Sichuan Kelun-Botai Biopharmaceutical Co., Ltd., presented multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin from October 17 to 21 [1] Group 1 - The clinical research results included data on targeted antibody-drug conjugates (ADCs) such as sac-TMT (Jiatailai®), targeting trophoblast cell surface antigen 2 (TROP2) [1] - The results also covered data on A166 (Shutailai®), a HER2-targeted ADC [1] - Additionally, data on SKB315, a Claudin18.2 (CLDN18.2) ADC, was presented [1]